UK, BioNTech collaborate to accelerate cancer vaccine trials
The collaboration will focus on the delivery of personalised cancer treatments, leveraging innovative immunotherapies that activate the body’s immune system
In a significant development towards advancing cancer treatments, the UK government has forged a major agreement with BioNTech SE, renowned for its collaboration with Pfizer in developing a Covid-19 vaccine.
The primary objective of this agreement is to propel the development of revolutionary cancer treatments.
Expanding upon a previous memorandum of understanding signed earlier this year, this partnership seeks to improve patients' access to cutting-edge cancer trials and therapies.
The collaboration will focus on the delivery of personalised cancer treatments, leveraging innovative immunotherapies that activate the body's immune system to identify and combat cancer cells.
The ultimate goal is to provide personalised treatment options to approximately 10,000 patients by the year 2030.
Notably, BioNTech SE has already initiated clinical trials in the UK, and further trials are set to commence in the coming years, with a larger number of patients expected to participate from 2026 onwards.
To bolster this research endeavour, BioNTech plans to establish advanced laboratories in Cambridge, staffed by a highly skilled team of scientists.
Additionally, a regional hub for the UK will be created. The partnership also includes the establishment of a Cancer Vaccine Launch Pad (CVLP) led by NHS England, in collaboration with Genomics England.
The CVLP aims to swiftly identify suitable NHS cancer patients who could potentially participate in personalised cancer vaccine trials.
Government officials, including prime minister Rishi Sunak, have expressed their enthusiasm for this landmark agreement, highlighting the potential for life-saving cancer treatments and underscoring the UK's leadership in the field of life sciences.
“The UK is a global leader in life sciences – helping to create thousands of highly skilled jobs and pioneering research - and it is testament to this success that BioNTech have chosen to make this significant investment here today,” Sunak said.
The partnership exemplifies the UK's appeal to innovative companies and reinforces the government's commitment to fostering research and development.
Of particular focus within this collaboration is the development of personalised mRNA-based cancer immunotherapies, a form of cancer treatment that activates the immune system of patients.
These immunotherapies can be designed to target common abnormalities found in a specific type of cancer or customised to suit the unique characteristics of an individual's tumour.
These treatments will be tailored to individual patients based on genomic analyses of their tumours, thereby maximising their efficacy.
The long-term vision is to revolutionise cancer care, improve patient outcomes, and potentially integrate cancer vaccines into standard treatment protocols.
The partnership endeavours to expedite the availability of new investigational cancer treatments from BioNTech to eligible UK cancer patients.
Various stakeholders, including NHS, Genomics England, and BioNTech SE, have commended this collaboration as a significant stride forward in the realm of cancer research and treatment.
It is anticipated to offer renewed hope and expanded possibilities for cancer patients.
The UK government's support for the life sciences sector and its unwavering dedication to research and development are instrumental in propelling advancements that yield substantial health benefits for patients.
This partnership marks a pivotal milestone in advancing cancer treatments, propelling the UK to the forefront of innovative cancer research.
By strengthening access to cutting-edge trials and therapies, this collaboration has the potential to revolutionise cancer care, benefiting not only patients in the UK but also individuals worldwide.
Later today, (06) prominent NHS cancer doctors from various regions of the UK will convene in Westminster to commemorate the inauguration of this remarkable partnership.
The gathering aims to celebrate the launch of the collaboration and provide an opportunity for the doctors to discuss their crucial roles in this significant development.
Casio releases a limited-edition version of the classic CA-500 calculator watch worn by Marty McFly.
Watch design features DeLorean-inspired details, multicoloured buttons and OUTATIME licence plate.
Special packaging resembles a vintage VHS tape; priced at £115 and available from 21 October 2025.
A nostalgic nod to time travel
To mark the 40th anniversary of Back to the Future, Casio has unveiled a special edition of its classic CA-500 calculator watch, worn by Marty McFly in the iconic film series. The new model, CA-500WEBF, revives the 1980s design with playful references to the DeLorean time machine and the film’s visual elements.
The watch face incorporates design cues from the DeLorean’s taillights and the OUTATIME licence plate, while the multicoloured calculator buttons are inspired by the glowing time circuits on Doc Brown’s dashboard.
Collector-friendly features
The limited edition watch also includes an engraved flux capacitor on the caseback and the Back to the Future logo on the buckle. The watch arrives in packaging designed to resemble a vintage VHS cassette, complete with faux rental labels, reflecting the way many fans first enjoyed the film.
Priced at £115, the watch is positioned as both a wearable piece of nostalgia and a collector’s item. Casio’s CA-500 design has been one of its longest-running models and was featured in the original film, giving the anniversary release added authenticity.
Release and availability
The CA-500WEBF goes on sale 21 October 2025, known to fans as Back to the Future Day, commemorating the date Marty McFly travelled to the future in Part II of the trilogy. The watch will be available in limited numbers online, allowing fans to either wear it or keep it in mint condition as a collector’s item.
Casio’s limited-edition release provides a tangible connection to the enduring legacy of a film that continues to inspire nostalgia and creativity across generations.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.